Eminence Capital LP Has $2.92 Million Position in Haleon plc (NYSE:HLN)

Eminence Capital LP boosted its holdings in Haleon plc (NYSE:HLN) by 8.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 353,717 shares of the company’s stock after buying an additional 26,094 shares during the period. Eminence Capital LP’s holdings in Haleon were worth $2,922,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of HLN. Cultivar Capital Inc. acquired a new position in Haleon in the second quarter valued at approximately $40,000. Allspring Global Investments Holdings LLC acquired a new position in Haleon in the first quarter valued at approximately $43,000. GAMMA Investing LLC lifted its holdings in Haleon by 151.3% in the first quarter. GAMMA Investing LLC now owns 6,106 shares of the company’s stock valued at $52,000 after buying an additional 3,676 shares during the period. Pinnacle Bancorp Inc. lifted its holdings in Haleon by 29.8% in the first quarter. Pinnacle Bancorp Inc. now owns 6,188 shares of the company’s stock valued at $53,000 after buying an additional 1,421 shares during the period. Finally, Hexagon Capital Partners LLC increased its stake in Haleon by 66.6% in the second quarter. Hexagon Capital Partners LLC now owns 6,695 shares of the company’s stock valued at $55,000 after purchasing an additional 2,677 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Morgan Stanley upped their target price on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Berenberg Bank assumed coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.95.

Haleon Stock Down 0.7 %

Shares of HLN stock opened at $10.59 on Thursday. The firm has a fifty day moving average of $9.87 and a 200-day moving average of $8.92. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.70 and a 12-month high of $10.76. The company has a market capitalization of $48.26 billion, a price-to-earnings ratio of 35.28, a P/E/G ratio of 3.12 and a beta of 0.26.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The company had revenue of $3.50 billion for the quarter, compared to the consensus estimate of $3.55 billion. During the same period in the prior year, the company earned $0.08 EPS. As a group, equities research analysts predict that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The firm also recently announced a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were given a $0.0514 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon’s dividend payout ratio (DPR) is currently 36.67%.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.